Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia

Hypertension Research

Volumn 33, Issue 10, 2010, Pages 1038-1043

  Lewandowski, Jacek ^a   Siński, MacIej ^a   Bidiuk, Joanna ^a   Abramczyk, Piotr ^a   Dobosiewicz, Anna ^a   Ciarka, Agnieszka ^b   Gaciong, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b ERASME HOSPITAL   (Belgium)

Author keywords

hypercholesterolemia; microneurography; statins; sympathetic activity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; NEUROPEPTIDE Y; RENIN; SIMVASTATIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; NEUROGRAPHY; OUTCOME ASSESSMENT; PRESSORECEPTOR REFLEX; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; STATISTICAL SIGNIFICANCE; SYMPATHETIC NERVE; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ALDOSTERONE; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; CATECHOLAMINES; COMORBIDITY; DOUBLE-BLIND METHOD; ENDOTHELINS; HEART RATE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; NEUROPEPTIDE Y; PRESSORECEPTORS; RENIN; SIMVASTATIN; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 77957717100     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.137     Document Type: Article

References (48)

1. Todd PA, Goa KL. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990; 40: 583-607.
2. Goldstein JI, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with CHD: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto Jr AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-1622.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
9. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or atorvastatin evaluation and infection therapy\thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
10. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipids lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
11. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003; 107: 2493-2498.
12. Hamaad A, Sosin M, Lip GY, Macfadyen RJ. Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 2005; 19: 183-187.
13. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005; 11: 684-690.
14. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 1979; 59: 919-957.
15. Watkins LL, Grossman P, Sherwood A. Noninvasive assessment of baroreflex control in borderline hypertension. Hypertension 1996; 28: 238-243.
16. Leeper NJ, Ardehali R, deGoma EM, Heidenreich PA. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation 2007; 116: 613-618.
17. Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, Sinzinger H, Mannarino E. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000; 36: 617-621.
18. Martinez-Gonzalez J, Raposo B, Rodriguez C, Badimon L. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and post-transcriptional regulation. Arterioscler Thromb Vasc Biol 2001; 21: 804-809.
19. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-1678.
20. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-279.
21. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, Schmetterer L, Dorner GT. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001; 85: 47-51.
22. Hernandez-Perera O, Perez-Sala O, Navarro-Antolin J, Sánchez- Pascuala R, Hernández G, D?́az C, Lamas S. Effects of the HMG CoA reductase inhibitors atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-2719.
23. Patel KP, Li YF, Hirooka Y. Role of nitric oxide in central sympathetic outflow. Exp Biol Med 2001; 226: 814-824.
24. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005; 112: 1763-1770.
25. Esler M, Jennings G, Biviano B, Lambert G, Hasking G. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 1986; 8: 39-43.
26. Somers VK, Mark AL, Abboud FM. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension 1988; 11: 608-612.
27. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 1989; 13: 870-877.
28. Przybylski J. Do arterial chemoreceptors play a role in the pathogenesis of hypertension? Med Hypotheses 1981; 20: 173-177.
29. Trzebski A. Arterial chemoreceptor reflex and hypertension. Hypertension 1992; 19: 562-566.
30. Bristow JD, Honour AJ, Pickering GW, Sleight P, Smyth HS. Diminished baroreflex sensitivity in high blood pressure. Circulation 1969; 39: 48-54.
31. Ribeiro MO, Antunes E, De-Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitricoxide synthesis: a new model of arterial hypertension. Hypertension 1992; 20: 298-303.
32. Baylis C, Mitruka B, Deng A. Chronic blockade ofnitricoxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-281.
33. Patterson D, Dick JB, Struthers AD. Intensive statin treatment improves baroreflex sensitivity: another cardioprotective mechanism for statins? Heart 2002; 88: 415-416.
34. Melenovsky V, Wichterle D, Simek J, Malik J, Haas T, Ceska R, Malik M. Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipi-demia. Am J Cardiol 2003; 92: 337-341.
35. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157: 463-469.
36. Gomes ME, Lenders JW, Bellersen L, Verheugt FW, Smits P, Tack CJ. Sympathoinhi-bitory effect of statins in chronic heart failure. Clin Auton Res 2009; 20: 73-78.
37. Szramka M, Harriss L, Ninnio D, Windebank E, Brack J, Skiba M, Krum H. The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease. Int J Cardiol 2007; 117: 287-291.
38. Zukowska-Grojec Z, Marks ES, Haass M. Neuropeptide Y is a potent vasoconstrictor and cardiodepressant in rat. Am J Physiol 1987; 253: 1234-1239.
39. Siñski M, Lewandowski J, Ciarka A, Bidiuk J, Abramczyk P, Dobosiewicz A, Gaciong Z. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension. Kardiol Pol 2009; 67: 613-620.
40. Calhoun DA, Mutinga ML, Wyss JM, Oparil S. Muscle sympathetic nervous activity in black and Caucasian hypertensive subjects. J Hypertens 1994; 12: 1291-1296.
41. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31: 68-72.
42. Wassmann S, Laufs U, Baumer AT, Müller K, Konkol C, Sauer H, Böhm M, Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59: 646-654.
43. Mortensen LH. Endothelin and the central and peripheral nervous systems: a decade of endothelin research. Clin Exp Pharmacol Physiol 1999; 26: 980-984.
44. Schultz HD, Li YL. Carotid body function in heart failure. Respir Physiol Neurobiol 2007; 157: 171-185.
45. Grassi G, Cattaneo B, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, Carugo S, Mancia G. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96: 1173-1179.
46. Beloka SP, Gouveia S, Gujic M, Naeije R, Rocha AP, van de Borne P. Differential effects of oral beta blockade on cardiovascular and sympathetic regulation. J Cardiovasc Pharmacol Ther 2009; 4: 323-331.
47. Burns J, Mary DA, Mackintosh AF, Ball SG, Greenwood JP. Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive. Hypertension 2004; 4: 454-458.
48. Binggeli C, Corti C, Sudano I, Luscher TH, Noll G. Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension 2002; 39: 892-896.